Trial Profile
Combination of Cetuximab & MWT Inhibitor Savolitinib in the Treatment of Ras Wild-Type Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Savolitinib (Primary)
- Indications Colorectal cancer; Head and neck cancer
- Focus Adverse reactions
- 24 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.
- 18 Dec 2015 New trial record